Floatz logo

[18F]ACI-15916

Multiple System Atrophy (MSA)

AC Immune SAEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Multiple System Atrophy (MSA) cohort.

Asset / SponsorPhaseRating
Droxidopa
Loma Linda University
Phase 3BB
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
IOFLUPANE
GE Healthcare
Phase 3B
ATH-434
Alterity Therapeutics
Phase 2B
Riluzole
King's College London
Phase 3B

View all 40 →

Same molecule, other indications

[18F]ACI-15916 is also rated in:

Lewy body dementiaDormant
C
Indicative ·
39 / 100
View asset →
Parkinson diseaseDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →